Novel translational approaches to the search for precision therapies for acute respiratory distress syndrome.
Novel translational approaches to the search for precision therapies for acute respiratory distress syndrome.
复制标题
DOI：
10.1016/s2213-2600(17)30187-x
复制
发表时间：
2017-06
期刊：
影响因子：
--
通讯作者：
Calfee CS
中科院分区：
文献类型：
--
作者：
Meyer NJ;Calfee CS
自急性呼吸窘迫综合征(ARDS)被首次描述以来的50年里，在确定ARDS的危险因素和致病因素以及表征ARDS患者血浆和支气管肺泡灌洗液中的蛋白质表达模式方面取得了实质性进展。然而，尽管做出了这样的努力，ARDS的药理选择仍然很少。缺乏特定药物治疗的常见原因包括ARDS患者的异质性，对药物的不同反应的可能性，以及研究错误靶点的可能性。应用生物分子技术和生物信息学的进步使其他复杂特征的突破成为可能，如心血管疾病或哮喘，特别是在追求精确医学范式的情况下，其中生物标记物或基因表达模式表明患者对治疗有效的可能性。在这篇综述中，我们考虑了可以促进ARDS的精确医学方法的生物学和分析技术。
In the 50 years since acute respiratory distress syndrome (ARDS) was first described, substantial progress has been made in identifying the risk factors for and the pathogenic contributors to the syndrome and in characterising the protein expression patterns in plasma and bronchoalveolar lavage fluid from patients with ARDS. Despite this effort, however, pharmacological options for ARDS remain scarce. Frequently cited reasons for this absence of specific drug therapies include the heterogeneity of patients with ARDS, the potential for a differential response to drugs, and the possibility that the wrong targets have been studied. Advances in applied biomolecular technology and bioinformatics have enabled breakthroughs for other complex traits, such as cardiovascular disease or asthma, particularly when a precision medicine paradigm, wherein a biomarker or gene expression pattern indicates a patient's likelihood of responding to a treatment, has been pursued. In this Review, we consider the biological and analytical techniques that could facilitate a precision medicine approach for ARDS.